HIV, pneumococcal — and what? Merck's unexpected pipeline highlight excites a little biotech
In an R&D update dominated by oncology — mostly Keytruda, followed by Lynparza and Lenvima — Merck chose to highlight a program in sensory pathology, an HIV drug, and a group of pneumococcal vaccines. And that has made at least one biotech very happy.
Basic subscription required
Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.